Adipose-derived stem cells in Crohn's rectovaginal fistula

D García-Olmo, D Herreros, P De-La-Quintana, H Guadalajara, J Trébol, T Georgiev-Hristov, M García-Arranz, D García-Olmo, D Herreros, P De-La-Quintana, H Guadalajara, J Trébol, T Georgiev-Hristov, M García-Arranz

Abstract

Therapeutic options for recto-vaginal fistula in the setting of Crohn's disease are limited and many data are available in the literature. The manuscript describes the history of a patient who has been the pioneer of our Clinical Trials in treating this disease in fistulizing Crohn's disease environment. We believe it is the first time that a patient with this disease has been treated by adipose-derived stem cells in allogeneic form. The conclusion of our study with Mary is that the use of mesenchymal stem cells derived from adipose tissue is secure, either in autologous or allogeneic form. Furthermore, we have proved that if we use multi-dose and multiple applications on a patient, it does not produce any adverse effect, which confirms us the safety of using these cells in patients at least in the fistulizing Crohn's disease environment.

Figures

Figure 1
Figure 1
Figure 2
Figure 2

References

    1. Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58(7):929–939.
    1. Levy C, Tremaine WJ. Management of internal fistulas in Crohn’s disease. Inflammatory Bowel Diseases. 2002;8(2):106–111.
    1. Penninckx F, D’Hoore A, Filez L. Advancement flap plasty for the closure of anal and recto-vaginal fistulas in Crohn’s disease. Acta Gastro-Enterologica Belgica. 2001;64(2):223–226.
    1. Reid R, Gallup DG. Local and distant skin flaps in the reconstruction of vulvar deformities. American Journal of Obstetrics and Gynecology. 1997;177(6):1372–1384.
    1. Rius J, Nessim A, Nogueras JJ, Wexner SD. Gracilis transposition in complicated perianal fistula and unhealed perineal wounds in Crohn’s disease. European Journal of Surgery. 2000;166(3):218–222.
    1. van Koperen PJ, Wind J, Bemelman WA, Bakx R, Reitsma JB, Slors JFM. Long-term functional outcome and risk factors for recurrence after surgical treatment for low and high perianal fistulas of cryptoglandular origin. Diseases of the Colon and Rectum. 2008;51(10):1475–1481.
    1. Parsi MA, Lashner BA. Safety of infliximab: primum non nocere. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Inflammatory Bowel Diseases. 2004;10:486–487.
    1. García-Olmo D, García-Arranz M, García LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perinatal Crohn’s disease: a new cell-based therapy. International Journal of Colorectal Disease. 2003;18(5):451–454.
    1. García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of crohn’s fistula by adipose mesenchymal stem cell transplantation. Diseases of the Colon and Rectum. 2005;48(7):1416–1423.
    1. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum. 2009;52(1):79–86.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅